The Direct Answer

BPC-157, short for Body Protection Compound-157, sits outside both of the UK's two main medicines frameworks that people tend to assume apply to it. It is not scheduled as a controlled drug under the Misuse of Drugs Act 1971, so it is not treated in the same legal category as anabolic steroids or opioids. At the same time, no product containing BPC-157 holds a Medicines and Healthcare products Regulatory Agency (MHRA) marketing authorisation, which means it has not been assessed by the MHRA for safety, quality, or efficacy for human use. Under the Human Medicines Regulations 2012, a product intended for human medicinal use that lacks that authorisation is an unlicensed medicinal product, and supplying it for that purpose without a valid route, such as a specials manufacturing licence or a prescription under the named-patient exemption, is a regulatory offence. "Not controlled" and "not licensed" describe two different legal facts, and BPC-157 in the UK is best described as the second, not the first.

Not a controlled drug is not the same statement as legal to sell for human use. BPC-157 in the UK is the second kind of unregulated: unlicensed, not uncontrolled-and-therefore-permitted.

Is BPC-157 Legal to Possess in the UK?

Personal possession of BPC-157 is not addressed by the Misuse of Drugs Act 1971, because the compound does not appear on any of that Act's schedules. This means possession does not carry the same criminal exposure as possessing a Class A, B, or C controlled substance. The relevant legal question shifts instead to the Human Medicines Regulations 2012, which primarily targets the act of manufacturing, importing for supply, advertising, or selling an unlicensed medicinal product for human use, rather than an individual holding a small quantity for themselves. This distinction between possession and supply is why UK enforcement activity in this space, carried out by the MHRA's Criminal Enforcement Unit, has historically focused on sellers and importers rather than individual buyers.

Why Doesn't BPC-157 Have an MHRA Marketing Authorisation?

A marketing authorisation is only granted after a manufacturer submits a full dossier of clinical and manufacturing data and the MHRA assesses it against safety, quality, and efficacy standards; no such dossier for BPC-157 has resulted in an authorised product in the UK. The underlying reason is the state of the research itself. The body of published BPC-157 literature, largely originating from a Croatian research group led by Sikirić and colleagues over several decades, is overwhelmingly preclinical, meaning it consists of laboratory and animal-model studies rather than completed, registered human clinical trials. A search of PubMed's indexed literature on BPC-157 reflects this pattern directly: the great majority of listed records are rodent studies. Without completed human trial data submitted through a formal licensing dossier, there is no regulatory pathway that would produce an MHRA-authorised product, regardless of demand.

Does Labelling It "Not for Human Consumption" Make It Legal to Sell?

No, and this is the point most sellers rely on and most buyers misunderstand. Under Regulation 2 of the Human Medicines Regulations 2012, whether a product counts as a "medicinal product" depends on its presentation and function, not solely on the wording printed on its label. A product marketed with health-related claims, sold in a format matching injectable research compounds, and purchased overwhelmingly for human use can still meet the legal definition of a medicinal product even if the packaging states "for laboratory research only, not for human use." Regulators assess the substance of how a product is marketed and used, not just its disclaimer text. This is why a printed disclaimer does not, by itself, resolve the underlying licensing question.

Is BPC-157 a Controlled Drug Under the Misuse of Drugs Act?

No. As covered above, BPC-157 does not appear on any schedule under the Misuse of Drugs Act 1971 or the accompanying Misuse of Drugs Regulations 2001. Its absence from that Act means it is not classified, tracked, or penalised in the way the UK treats controlled substances, and it is not subject to the same possession or trafficking offences. This is frequently the fact that gets cited online as proof BPC-157 is "legal," but the Misuse of Drugs Act is only one of two relevant frameworks. The Human Medicines Regulations 2012 is the framework that actually governs its status, and on that framework it remains unlicensed for human use.

Is BPC-157 Banned in UK Sport?

Yes, for any athlete subject to testing. This is the clearest piece of concrete regulatory detail in BPC-157's UK status, and it sits outside the medicines/controlled-drug question entirely. The World Anti-Doping Agency added BPC-157 to its Prohibited List under category S0, Non-Approved Substances, starting with the 2022 List, a category that automatically captures any pharmacological substance without approval by a governmental health authority for human therapeutic use, precisely the situation described above. UK Anti-Doping, the national body responsible for testing under the UK's national anti-doping policy, applies the WADA Prohibited List in full. A UK athlete testing positive for BPC-157 therefore faces an anti-doping rule violation independent of whether the substance itself is a controlled drug or how it was obtained.

What Does the Research Evidence Actually Show?

The published evidence base is real but narrow in scope. Decades of animal-model research, much of it from the same originating research group, has examined BPC-157 across gastrointestinal, tendon, and wound-healing models, and this body of work is what sustains ongoing scientific interest in the compound. What is absent is the next stage regulators require: completed, peer-reviewed human clinical trials assessing safety and efficacy in people, of the kind that would normally support a marketing authorisation dossier submitted to the MHRA or, in the EU, assessed by the European Medicines Agency. Preclinical promise and regulatory approval are separate stages, and BPC-157 has not crossed from one to the other in any jurisdiction relevant to UK buyers.

BPC-157 UK Status — At a Glance

Misuse of Drugs Act 1971 — not scheduled. Not treated as a controlled drug.

Human Medicines Regulations 2012 — no MHRA marketing authorisation exists. Unlicensed for human use; supply for that purpose without a valid exemption is an offence.

Labelling as "research use only" — does not override the regulatory test, which looks at actual presentation and use, not label wording alone.

WADA Prohibited List — listed under S0, Non-Approved Substances, since 2022. Banned for UK athletes subject to testing.

Clinical trial status — predominantly preclinical animal-model research; no completed human trials underpinning a UK or EU licensing dossier.

Summary

BPC-157's UK legal status is best understood as two separate answers to two separate questions. It is not a controlled drug under the Misuse of Drugs Act 1971, so possession does not carry that category of criminal exposure. It is, however, an unlicensed medicinal product under the Human Medicines Regulations 2012, because no MHRA marketing authorisation exists for it, and a "not for human consumption" label does not change that classification when the product's real presentation and use say otherwise. Separately, and regardless of the medicines framework, BPC-157 has been on the WADA Prohibited List since 2022, making it a banned substance for any UK athlete subject to testing. For further background on how the MHRA framework applies to research peptides generally, see our guide to MHRA regulations on peptides in the UK. Always consult a licensed healthcare professional before making any decision involving an unlicensed compound.